Founded with the mission to cure hair loss, dNovo leverages cutting-edge cellular reprogramming technology developed at Stanford and Harvard. The company focuses on converting patient-derived cells, such as blood, skin, or fat, into medically relevant cell types. Their primary product aims to address hair loss by creating new hair through this innovative technology. dNovo's broader vision includes using their reprogramming techniques to potentially create organs on demand, positioning them at the forefront of regenerative medicine.

Notable affiliations include pioneering researchers from Stanford and Harvard, who have significantly contributed to the development of dNovo's technology. The company holds a patent pending for their hair regeneration method. dNovo's impact is marked by its potential to revolutionize treatments for hair loss and other age-related conditions, offering a promising alternative to existing solutions. Their advancements in cellular reprogramming could pave the way for future breakthroughs in regenerative medicine.